Guo Xueran

TL;DR: The E6F6-like mAbs may provide a novel immunotherapeutic agent against human chronic HBV infection and was possibly associated with its effective in vivo opsonophagocytosis for viral clearance.

TL;DR: A cell-penetrating whole molecule antibody targeting HBx (9D11-Tat) by the fusion of a cell penetrating peptide on the C-terminus of the heavy chain of a potent mAb specific to HBx is developed, offering a new approach to target intracellular pathogenesis-related protein by engineered cell- penetrating mAb expanding their potential for therapeutic applications.

TL;DR: This new humanised mouse model recapitulates the liver cirrhosis induced by human HBV infection, thus providing research opportunities for understanding viral immune pathophysiology and testing antiviral therapies in vivo.

TL;DR: The novel particulate protein CR-T3-SEQ13 suppressed HBsAg effectively through induction of a humoural immune response in HBV-tolerant mice and may provide a novel immunotherapeutic agent against chronic HBV infection in humans.

TL;DR: The baseline anti-pp150 IgG was negatively correlated with the risk of H CMV infection and could be an excellent predictor of HCMV infection in HCMVs seropositive populations.